Learn about our expanded patient care options for your health care needs.
General Information | Self-Checker | Donate and Lend Support | Staff Appreciation
Enter the last name, specialty or keyword for your search below.
The Amita Gupta Lab focuses on drug trials to prevent and treat HIV, tuberculosis (TB) and other co-morbidities in adults, including pregnant women and children who reside in low-income settings. We also conduct cohort studies assessing HIV, inflammation and nutrition in international settings; TB in pregnancy; and risk factors for TB in India (CTRIUMPH). We collaborate with several faculty in the Center for TB Research, Division of Infectious Diseases and the School of Public Health.
Research in the Andrea Cox Lab explores the immune response in chronic viral infections, with a focus on HIV and the hepatitis C virus (HCV). In our studies, we examine the role of the immune response upon exposure to HCV by examining responses to HCV in a longitudinal, prospective group of high-risk individuals. This enables us to compare the innate, humoral and cellular immune responses to infection with clearance versus persistence. Through our findings, we seek to identify mechanisms of protective immunity against HCV infection and improve HCV vaccine design.
The Anna Durbin Lab evaluates experimental vaccines through human clinical trials. We have conducted both pediatric and adult clinical trials on vaccines for HIV, hepatitis C, HPV, influenza, malaria, dengue virus, rotavirus and other viruses. We also have a longstanding interest in better understanding the immunologic factors of dengue infection and disease. We’re working to identify the viral, host and immunologic factors that cause severe dengue illness.
Research in the Anne Rompalo Lab focuses on STD research and application. We recently examined the relationship between violence against women and HIV-related risk factors in women living in the United States. Past projects include a nine-year longitudinal observation study of HIV-infected women in Baltimore.
The Balagopal Lab has adapted high-resolution tools to study viruses in situ. Specifically, we were the first to quantify hepatitis C virus (HCV) infection in single hepatocytes by developing single-cell laser capture microdissection (scLCM) and integrating this tool with highly sensitive quantitative real-time PCR. We reported that HCV infects a minority of hepatocytes that are found in geospatial clusters. More recently, we (PIs Balagopal and Thio) integrated scLCM with droplet digital PCR (ddPCR) to reveal the first observations of hepatitis B virus (HBV) infection at single cell resolution in the liver. We found that HBV infects nearly all hepatocytes prior to antiviral therapy. However, during antiviral therapy, HBV infection is diminished while viral transcription is markedly attenuated.
Our lab has also focused on HIV-1 infection and immune activation for over a decade. Most recently, we have studied type 1 interferon responses to HIV-1 using RNA sequencing (RNAseq). Using th...is technology, we identified novel interferon-stimulated genes (ISGs) that are associated with HIV-1 restriction in vivo. view less
The Bryan Lau Lab is interested in epidemiological and statistical methods for cohort studies and the application of these methods primarily to HIV cohort studies. We’re particularly interested in developing new methods and using approaches from other disciplines as novel solutions to specific epidemiologic issues.
A. Laboratory activities include the use of accelerator mass spectrometry (AMS) techniques to measure intracellular drugs and drugs metabolites. AMS is a highly sensitive method for detecting tracer amounts of radio-labeled molecules in cells, tissues, and body fluids. We have been able to measure intracellular zidovudine triphosphate (the active anabolite of zidovudine) in peripheral blood mononuclear cells from healthy volunteers given small doses of 14C-zidovudine, and have directly compared the sensitivity of AMS to traditional LC/MS methods carried out in our laboratory.
B. Clinical research activities investigate the clinical pharmacology of new anti-HIV therapies and drug combinations. Specific drug classes studied include HIV reverse transcriptase inhibitors, protease inhibitors, entry inhibitors (selective CCR5 and CXCR4 antagonists), and integrase inhibitors. Scientific objectives of clinical studies include characterization of early drug activity, toxicity, and pharmacok...inetics. Additional objectives are characterization of pathways of drug metabolism, and identification of clinically significant harmful and beneficial drug interactions mediated by hepatic and intestinal cytochrome P450 isoforms. view more
Research in the Chloe Thio lab focuses on several areas. First, HBV virology and immunology in HBV monoinfected and HIV-HBV co-infected individuals that will ultimately help develop a cure for HBV. Second, HCV infection in men who have sex with men. Third, non-alcoholic fatty liver disease with a focus on HIV-infected individuals. Fourth, host genetic determinants of spontaneous HBV recovery and HCV clearance.
Work in the Christian Merlo Lab includes studies on pulmonary arteriovenous malformations, outcomes in lung transplantation and treatment of cystic fibrosis (CF), and HIV-related pulmonary disease. We have studied methods of diagnosing and managing pulmonary arteriovenous malformations as well as the outcomes of adult CF patients who are infected with multiple antibiotic-resistant Pseudomonas aeruginosa. Our recent research has also explored recipient and donor variables in the success or failure of lung transplants, and ways in which national healthcare delivery systems impact lung transplant outcomes for CF patients.
Dr. Christine Durand, assistant professor of medicine and oncology and member of the Johns Hopkins Kimmel Cancer Center, is involved in clinical and translational research focused on individuals infected with HIV and hepatitis C virus who require cancer and transplant therapies. Her current research efforts include looking at outcomes of hepatitis C treatment after solid organ transplant, the potential use of organs from HIV-infected donors for HIV-infected solid organ transplant candidates, and HIV cure strategies including bone marrow transplantation.
Dr. Durand is supported by multiple grants:
• R01 from the National Institute of Allergy and Infectious Diseases (NIAID) to study HIV-to-HIV organ transplantation in the US.
• K23 from the National Cancer Institute (NCI) to study antiretroviral therapy during bone marrow transplant in HIV-1 infection.
• U01 from the NIAID to study HIV-to-HIV deceased donor kidney transplantation.
U01 from the NIAID to study HIV-to-HIV deceased ...donor liver transplantation. view more
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
